# EDGAR Filing Document

**Accession Number:** 0001872812
**File Stem:** 0001493152-23-001158
**Filing Date:** 2023-1
**Character Count:** 3482
**Document Hash:** 74883b99f4f7f798f093c741e20548f5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-001158.hdr.sgml**: 20230111

**ACCESSION NUMBER**: 0001493152-23-001158

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230111

**FILED AS OF DATE**: 20230111

**DATE AS OF CHANGE**: 20230111

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TC BioPharm (Holdings) plc
- **CENTRAL INDEX KEY:** 0001872812
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41231
- **FILM NUMBER:** 23523250

**BUSINESS ADDRESS:**
- **STREET 1:** MAXIM 1
- **STREET 2:** 2 PARKLANDS WAY
- **CITY:** HOLYTOWN
- **STATE:** X0
- **ZIP:** ML1 4WR
- **BUSINESS PHONE:** 01414337557

**MAIL ADDRESS:**
- **STREET 1:** MAXIM 1
- **STREET 2:** 2 PARKLANDS WAY
- **CITY:** HOLYTOWN
- **STATE:** X0
- **ZIP:** ML1 4WR

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TC BioPharm (Holdings) Ltd
- **DATE OF NAME CHANGE:** 20210721

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TC BioPharm Ltd
- **DATE OF NAME CHANGE:** 20210714

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **January 2023**

**Commission File Number 001-41231**

**TC BIOPHARM (HOLDINGS) PLC**

(Translation of registrant's name into English)

**Maxim 1, 2 Parklands Way**

**Holytown, Motherwell, ML1 4WR**

**Scotland, United Kingdom**

**+44 (0) 141 433 7557**

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ ☐ <br>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ ☐

On December 6, 2022, TC Biopharm (Holdings) plc (the "Company") received written notification from the listing qualifications staff of the Nasdaq Stock Market, LLC ("Nasdaq") indicating that the Company regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules and that this matter is now closed.

As previously announced, on July 12, 2022, Nasdaq notified the Company of its non-compliance with the minimum closing bid price requirement for its American Depositary Shares (the "ADSs") because the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company had a compliance period of 180 calendar days, or until January 9, 2023, to regain compliance with Nasdaq's minimum bid price requirement.

**Signature**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **TC BIOPHARM (HOLDINGS) PLC** | **TC BIOPHARM (HOLDINGS) PLC** |
|  | By: | */s/ Martin Thorp* |
|  | Name: | Martin Thorp |
|  | Title: | Chief Financial Officer |
| Date: January 11, 2023 |  |  |

---